Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets (Tables)

v3.7.0.1
Other Intangible Assets (Tables)
 6 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of June 30, 2017 and December 31, 2016 are as follows:

 

        As of
June 30, 2017 		    As of
December 31, 2016 		 
    Life   Carrying     Carrying  
    (Years)   Amount     Amount  
Diagnostic assets:                    
Asuragen acquisition:                    
Thyroid   9   $ 8,519     $ 8,519  
Pancreas   -     -       -  
Biobank   -     -       -  
RedPath acquisition:                    
Pancreas test   7     16,141       16,141  
Barrett's test   9     18,351       18,351  
Total       $ 43,011     $ 43,011  
Diagnostic lab:                    
CLIA Lab   2.3   $ 609     $ 609  
                     
Accumulated Amortization       $ (8,888 )   $ (7,262 )
                     
Net Carrying Value       $ 34,732     $ 36,358

Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2017     2018     2019     2020     2021  
$ 3,252     $ 3,252     $ 5,292     $ 5,292     $ 4,908